NASDAQ · Biotechnology

Candel Therapeutics Inc (CADL)

$5.04 -1.75%
27 Oversold Daily RSI (14) · 18 Nov 2026

Moving averages

SMA 200$8.37-39.78%

Company profile

Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform, which uniquely targets and destroys cancer cells while preserving healthy tissue. The company has developed a promising pipeline that addresses several challenging malignancies, enhancing the body’s immune response against tumors and striving for significant advancements in therapeutic efficacy. With a solid intellectual property foundation and strategic collaborations with leading research institutions, Candel is well-positioned to be at the forefront of groundbreaking innovations in oncology, with the ultimate goal of improving patient outcomes and reshaping cancer care standards.

SectorHealthcare
IndustryBiotechnology
Market cap$705.50M
P/E ratioNone
EPS$-1.46
Beta-0.287
Dividend yield0.00%
52-week high$14.00
52-week low$4.35

Similar stocks in Biotechnology

30 days of PRO Unlimited free, no card

RSI alerts for CADL

An email when CADL closes below RSI 30 or above 70. Nothing else.

Data last updated 13 November 2026 at 7:12 AM EST